Basic Information
| LncRNA/CircRNA Name | PANDA |
| Synonyms | PANDAR, PANDA |
| Region | GRCh38_6:36673621-36675126 |
| Ensemble | ENSG00000281450 |
| Refseq | NR_109836 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | diffuse large B-cell lymphoma |
| ICD-0-3 | NA |
| Methods | HiSeq, qPCR, Western blot, Luciferase reporter assay, ChIP etc. |
| Sample | lymph node tissues, cell lines (U2932, SUDHL-6, SUDHL-3, OCI-Ly3, and OCI-Ly8) |
| Expression Pattern | down-regulated |
| Function Description | Luciferase reporter assay and chromatin immunoprecipitation assay suggested that lncRNA PANDA was induced by p53 and p53 interacts with the promoter region of PANDA.Cell functional assay further indicated that PANDA functioned as a tumor suppressor gene through the suppression of cell growth by a G0/G1 cell cycle arrest in DLBCL. More importantly, Cignal Signal Transduction Reporter Array and western blot assay showed that lncRNA PANDA inactivated the MAPK/ERK signaling pathway. In conclusion, our integrated approach demonstrates that PANDA in DLBCL confers a tumor suppressive function through inhibiting cell proliferation and silencing MAPK/ERK signaling pathway. Thus, PANDA may be a promising therapeutic target for patients with DLBCL. |
| Pubmed ID | 29069778 |
| Year | 2107 |
| Title | Discovery and validation of the tumor-suppressive function of long noncoding RNA PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPK/ERK signaling pathway. |
External Links
| Links for PANDA | GenBank HGNC NONCODE |
| Links for diffuse large B-cell lymphoma | OMIM COSMIC |